Research Article

You have full text access to this OnlineOpen article

Predictors and outcomes of scleroderma renal crisis: The high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial

  1. Paul J. DeMarco1,
  2. Michael H. Weisman2,
  3. James R. Seibold3,
  4. Daniel E. Furst4,
  5. Weng Kee Wong5,
  6. Eric L. Hurwitz5,
  7. Maureen Mayes6,
  8. Barbara White7,
  9. Fredrick Wigley8,
  10. Walter Barr9,
  11. Larry Moreland10,
  12. Thomas A. Medsger Jr.11,
  13. Virginia Steen12,
  14. Richard W. Martin13,
  15. David Collier14,
  16. Arthur Weinstein15,
  17. Edward Lally16,
  18. John Varga17,
  19. Steven R. Weiner4,
  20. Brian Andrews18,
  21. Micha Abeles19,
  22. Philip J. Clements4,*

Article first published online: 8 NOV 2002

DOI: 10.1002/art.10589

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 46, Issue 11, pages 2983–2989, November 2002

Additional Information

How to Cite

DeMarco, P. J., Weisman, M. H., Seibold, J. R., Furst, D. E., Wong, W. K., Hurwitz, E. L., Mayes, M., White, B., Wigley, F., Barr, W., Moreland, L., Medsger, T. A., Steen, V., Martin, R. W., Collier, D., Weinstein, A., Lally, E., Varga, J., Weiner, S. R., Andrews, B., Abeles, M. and Clements, P. J. (2002), Predictors and outcomes of scleroderma renal crisis: The high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis & Rheumatism, 46: 2983–2989. doi: 10.1002/art.10589

Author Information

  1. 1

    Marshfield Clinic, Wausau, Wisconsin

  2. 2

    Cedars–Sinai Medical Center, Los Angeles, California

  3. 3

    University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical School, New Brunswick

  4. 4

    University of California, Los Angeles, School of Medicine

  5. 5

    University of California, Los Angeles, School of Public Health

  6. 6

    University of Texas, Houston

  7. 7

    University of Maryland School of Medicine, Baltimore

  8. 8

    The Johns Hopkins University, Baltimore, Maryland

  9. 9

    Northwestern University Medical School, Chicago, Illinois

  10. 10

    University of Alabama at Birmingham

  11. 11

    University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

  12. 12

    Georgetown University Medical Center, Washington, DC

  13. 13

    Michigan State University College of Human Medicine, Grand Rapids

  14. 14

    University of Colorado Health Sciences Center, Denver

  15. 15

    George Washington University Medical Center, Washington, DC

  16. 16

    Brown University School of Medicine, Roger Williams General Hospital, Providence, Rhode Island

  17. 17

    University of Illinois, Chicago

  18. 18

    University of California, Irvine

  19. 19

    University of Connecticut Health Center, Farmington

*University of California, Los Angeles, School of Medicine, 32-59 Rehabilitation Building, 1000 Veteran Avenue, Los Angeles, CA 90095-1670

Publication History

  1. Issue published online: 8 NOV 2002
  2. Article first published online: 8 NOV 2002
  3. Manuscript Accepted: 15 JUL 2002
  4. Manuscript Received: 8 JAN 2002

Funded by

  • Scleroderma Federation
  • United Scleroderma Foundation
  • FDA Orphan Drug Program
  • Arthritis Foundation
  • CRC. Grant Numbers: M01-RR-00865, M01-RR-00827
  • Winifred Krause
  • Morris Goldsmith
  • Takako Ito

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (86K)

REFERENCES

  • 1
    Steen VD. Organ involvement: renal. In: ClementsPJ, FurstDE, editors. Systemic sclerosis. Baltimore: Williams and Wilkins; 1996. p. 425–40.
  • 2
    Steen VD, Medsger TA Jr, Osial TA, Ziegler GL, Shapiro AP, Rodnan GP. Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 1984; 76: 779–86.
  • 3
    Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990; 113: 352–7.
  • 4
    Steen VD, Medsger TA Jr. Case–control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998; 41: 1613–9.
    Direct Link:
  • 5
    Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 2000; 43: 2445–54.
    Direct Link:
  • 6
    Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999; 42: 1194–203.
    Direct Link:
  • 7
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581–90.
    Direct Link:
  • 8
    Nagelkerke NJD. A note on a generalized definition of the coefficient of determination. Biometrika 1991; 78: 691–2.
  • 9
    Giersson AJ, Wollheim FA, Akesson A. Disease severity of 100 patients with systemic sclerosis over a period of 14 years: using a modified Medsger scale. Ann Rheum Dis 2001; 60: 1117–22.
  • 10
    Lunseth JH, Baker LA, Shifrin A. Chronic scleroderma with acute exacerbation during corticotropin therapy. Arch Intern Med 1951; 88: 783–92.
View Full Article (HTML) Get PDF (86K)